


HEALTHCARE

The Cancer Market Outlook to 2011

By Melissa Zebrowski

 [Table of Contents](#)

Melissa Zebrowski

Melissa Zebrowski has 7 years of experience in healthcare and pharmaceutical policy. During this time she has worked for 4 years as a consultant providing market research services in developed and emerging markets. Currently she is working as a pharmaceutical market analyst.

Copyright © 2006 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

The Cancer Market Outlook to 2011

Executive Summary	10	
Patient potential	10	
Global market analysis	11	
Analysis of potential future cancer blockbusters	12	
Leading players in the cancer market	13	
Chapter 1	Patient potential	16
Summary		16
Introduction		17
Disease description		17
Defining patient potential		19
Limitations of cancer epidemiology data		19
Lung cancer		20
Disease description		20
Epidemiology		23
Forecast prevalence		24
Colorectal cancer		25
Disease description		25
Epidemiology		27
Forecast prevalence		28
Breast cancer		30
Disease description		30
Epidemiology		32
Forecast prevalence		33
Ovarian cancer		35
Disease description		35
Epidemiology		36
Forecast prevalence		37
Uterine and cervical cancer		39
Disease description		39
Epidemiology		40
Forecast prevalence		41

Introduction	138
Analysis of the top 10 cytostatic hormonal therapies	141
Market analysis by drug class	144
LHRH agonists	144
Aromatase inhibitors	149
Anti-estrogens	155
Anti-androgens	159
Cytostatic hormonal therapies sales forecasts to 2011	161
Cancer market forecasts to 2011	162

Chapter 3 Analysis of potential future cancer blockbusters 164

Summary	164
Introduction	165
Drug profiles	166
Phase II pipeline drugs	166
Volociximab (M200)	166
Phase III pipeline drugs	168
Zarnestra (tipifarnib)	168
Sarasar (lonafarnib)	170
Tykerb (lapatinib)	171
Enzastaurin	173
Tasigna (nilotinib)	174
Zactima (vandetanib)	176
Javlor (vinflunine)	178
BiovaxID	179
Drugs in registration	181
Panitumumab	181
Gardasil and Cervarix	183
Recently marketed drugs	185
Tarceva (erlotinib)	185
Sutent (sunitinib)	188
Nexavar (sorafenib)	190
Sprycel (dasatinib)	192

Chapter 4 Leading players in the cancer market 196

Summary	196
Introduction	197
Global market shares	198

Roche	201
Marketed portfolio	201
R&D compounds	203
Cancer portfolio sales forecasts	205
Sanofi-Aventis	206
Marketed portfolio	206
R&D compounds	207
Cancer portfolio sales forecasts	209
Amgen	210
Marketed portfolio	210
R&D compounds	211
Cancer portfolio sales forecasts	212
AstraZeneca	213
Marketed portfolio	213
R&D compounds	214
Cancer portfolio sales forecasts	216
Novartis	218
Marketed portfolio	218
R&D compounds	220
Cancer portfolio sales forecasts	221
Johnson & Johnson	222
Marketed portfolio	222
R&D compounds	224
Cancer portfolio sales forecasts	225
Schering-Plough	227
Marketed portfolio	227
R&D compounds	228
Cancer portfolio sales forecasts	229
Lilly	231
Marketed portfolio	231
R&D compounds	232
Cancer portfolio sales forecasts	233

Chapter 5 Appendix 236

Glossary	236
Index	241

List of Figures

Figure 1.1:	Overview of the etiology of cancer	18
Figure 2.2:	Competitive dynamics of the major classes in the global cancer market, 2004–05	65
Figure 2.3:	Competitive dynamics of the leading drugs in the global cancer market, 2004–05	67
Figure 2.4:	Competitive dynamics of the major antineoplastic classes in the global cancer market, 2004–05	71
Figure 2.5:	Competitive dynamics of the leading antineoplastic brands in the global cancer market, 2004–05	74
Figure 2.6:	Competitive dynamics of drug classes within the global immunostimulant market, 2005	115
Figure 2.7:	Competitive dynamics of the leading immunostimulant brands in the global cancer market, 2004–05	118
Figure 2.8:	Competitive dynamics of the leading immunosuppressant brands in the global cancer market, 2004–05	133
Figure 2.9:	Competitive dynamics of drug classes within the global cytostatic hormonal therapy market, 2005	140
Figure 2.10:	Competitive dynamics of the leading cytostatic hormonal therapy brands in the global cancer market, 2004–05	143
Figure 3.11:	High potential drugs in late-stage development or that have been recently launched	165
Figure 4.12:	Key players in the global cancer market, 2001 & 2005	200

List of Tables

Table 1.1:	Epidemiology of lung cancer across the seven major markets, 2005	23
Table 1.2:	Forecast epidemiology of lung cancer across the seven major markets, 2006-11	24
Table 1.3:	Epidemiology of colorectal cancer across the seven major markets, 2005	27
Table 1.4:	Forecast epidemiology of colorectal cancer across the seven major markets, 2006-11	29
Table 1.5:	Epidemiology of breast cancer across the seven major markets, 2005	32
Table 1.6:	Forecast epidemiology of breast cancer across the seven major markets, 2006-11	34
Table 1.7:	Epidemiology of ovarian cancer across the seven major markets, 2005	37
Table 1.8:	Forecast epidemiology of ovarian cancer across the seven major markets, 2006-11	38
Table 1.9:	Epidemiology of uterine cancer across the seven major markets, 2005	40
Table 1.10:	Forecast epidemiology of uterine cancer across the seven major markets, 2006-11	42
Table 1.11:	Epidemiology of leukemia across the seven major markets, 2005	45
Table 1.12:	Forecast epidemiology of leukemia across the seven major markets, 2006-11	46
Table 1.13:	Forecast epidemiology of prostate cancer across the seven major markets, 2006-11	51
Table 1.14:	Epidemiology of pancreatic cancer across the seven major markets, 2005	53
Table 1.15:	Forecast epidemiology of pancreatic cancer across the seven major markets, 2006-11	55
Table 1.16:	Estimated epidemiology of lymphomas across the seven major markets, 2005	57
Table 1.17:	Forecast epidemiology of lymphomas across the seven major markets, 2006-11	59
Table 2.18:	Breakdown of the global cancer market by drug class, 2001–05	64
Table 2.19:	Leading products in the global cancer market, 2004–05	66

Table 2.20:	Breakdown of the global antineoplastics market by drug class, 2001–05	69
Table 2.21:	Leading therapies in the global antineoplastics market, 2004–05	72
Table 2.22:	Sales forecast for antineoplastic drug classes in the global cancer market, 2005–11	112
Table 2.23:	Breakdown of the global immunostimulants market by drug class, 2001–05	114
Table 2.24:	Sales of leading immunostimulant brands, 2004–05	116
Table 2.25:	Sales forecasts for immunostimulants in the global market,	128
Table 2.26:	Breakdown of the global immunosuppressant market by drug class, 2001–05	130
Table 2.27:	Sales of leading immunosuppressant brands, 2004–05	131
Table 2.28:	Sales forecast for immunosuppressive agents in the global market, 2005–11	137
Table 2.29:	Breakdown of the global cytostatic hormonal therapies market by drug class, 2001–05	139
Table 2.30:	Leading cytostatic hormonal therapy products in the global cancer market, 2004–05	141
Table 2.31:	Sales forecast for cytostatic hormonal therapy drug classes in the global market, 2005–11	161
Table 2.32:	Sales forecasts for the global cancer market by drug class, 2005–11	162
Table 4.33:	Key players in the global cancer market, 2001–2005	198
Table 4.34:	Roche’s marketed cancer portfolio, 2005	201
Table 4.35:	Roche’s cancer R&D pipeline, 2006	203
Table 4.36:	Forecast sales for Roche’s global cancer portfolio, 2005–11	205
Table 4.37:	Sanofi-Aventis’ marketed cancer portfolio, 2005	206
Table 4.38:	Sanofi-Aventis’ cancer R&D pipeline, 2006	208
Table 4.39:	Forecast sales for Sanofi-Aventis’ global cancer portfolio, 2005–11	209
Table 4.40:	Amgen’s marketed cancer portfolio, 2005	210
Table 4.41:	Amgen’s cancer R&D pipeline, 2006	211
Table 4.42:	Forecast sales for Amgen’s global cancer portfolio, 2005–11	212
Table 4.43:	AstraZeneca’s marketed cancer portfolio, 2005	213
Table 4.44:	AstraZeneca’s cancer R&D pipeline, 2006	215
Table 4.45:	Forecast sales for AstraZeneca’s global cancer portfolio, 2005–11	216
Table 4.46:	Novartis’ marketed cancer portfolio, 2005	218
Table 4.47:	Novartis’ cancer R&D pipeline, 2006	220
Table 4.48:	Forecast sales for Novartis’ global cancer portfolio, 2005–11	221
Table 4.49:	J&J’s marketed cancer portfolio, 2005	222
Table 4.50:	J&J’s cancer R&D pipeline, 2006	224
Table 4.51:	Forecast sales for J&J’s global cancer portfolio, 2005–11	225
Table 4.52:	Schering-Plough’s marketed cancer portfolio, 2005	227
Table 4.53:	Schering-Plough’s cancer R&D pipeline, 2006	228
Table 4.54:	Forecast sales for Schering-Plough’s global cancer portfolio,	229
Table 4.55:	Lilly’s marketed cancer portfolio, 2005	231
Table 4.56:	Lilly’s cancer R&D pipeline, 2006	232
Table 4.57:	Forecast sales for Lilly’s global cancer portfolio, 2005–11	233